Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation

This publication has 17 references indexed in Scilit:

• The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study
  Alimentary Pharmacology & Therapeutics, 2004
• An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome
  Gut, 2003
• Relapse of symptoms following withdrawal of tegaserod treatment in irritable bowel syndrome with constipation (IBS-C)
  Gastroenterology, 2003
• The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects
  Alimentary Pharmacology & Therapeutics, 2003
• A randomized, double‐blind, placebo‐controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation
  Alimentary Pharmacology & Therapeutics, 2002
• Tegaserod, a 5‐HT₄ receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects
  Alimentary Pharmacology & Therapeutics, 2001
• Irritable bowel syndrome: new pharmaceutical approaches to treatment
  Best Practice & Research Clinical Gastroenterology, 1999
• Irritable bowel syndrome
  Current Treatment Options in Gastroenterology, 1999
• Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate.
  BMJ, 1990